GALT, US3632252025

Galectin Therapeutics seeks 250 million shares: what it means for Galectin Therapeutics stock

Published on 10/06/2026 at 04:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A July conversion eliminated USD 91.0 million of principal. For Galectin Therapeutics stock, the proposal would authorize 250 million shares.

GALT, US3632252025, Illustration mit AI erstellt.

Galectin Therapeutics plans to seek approval for 250 million authorized common shares, up from 150 million, making the proposed charter amendment the central item for Galectin Therapeutics stock. The preliminary proxy filed on October 2, 2026, sets the virtual shareholder meeting for December 3, 2026, according to StockTitan.

Share authorization rises 66.67 percent

The proposal would add 100 million shares to the existing 150 million authorization, a calculated increase of 66.67 percent. It also seeks approval for 3 million additional shares under the 2019 Omnibus Equity Incentive Plan, while 11 director nominees are standing for election at the same meeting, the proxy statement says.

Shareholders of record on October 6, 2026, are eligible to vote. The filing states that 100,849,644 common shares were outstanding on the record date, alongside Series A convertible preferred shares that vote on an as-converted basis.

Debt conversion changes the capital picture

The proxy also describes a July 31, 2026, debt conversion that exchanged notes for 34,376,167 common shares. The transaction eliminated USD 91.0 million of principal and USD 14.8 million of accrued interest, according to StockTitan. The additional authorization would give the company more flexibility for equity compensation and future financing, but it also creates a clear dilution question because the requested ceiling would be 2.50 times the present authorization.

Second-quarter loss remains a counterweight

Galectin Therapeutics reported a second-quarter loss per share of USD 0.14 versus a consensus loss of USD 0.09, a USD 0.05 miss, as reported by MarketBeat. That result leaves financing capacity and clinical execution as the practical counterweights to the proposed capital increase.

Galectin Therapeutics describes itself as a biotechnology company developing therapies for chronic liver disease and cancer, with belapectin as its leading clinical candidate, according to Galectin Therapeutics.

Market value and dilution math

Galectin Therapeutics had a market capitalization of USD 245.6 million as of October 5, 2026, with a 52-week range of USD 2.03 to USD 7.13. The proposed 250 million authorization would stand 66.67 percent above the current 150 million ceiling, while the annual meeting date provides the next defined corporate milestone.